Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTVKILB)

• DTT Name: Prostaglandin G/H synthase 2 (COX-2) DTT Info
• Gene Name: PTGS2

Molecule-Related Drug & Molecule List

27 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aminosalicylic Acid	DMENSL5	Crohn disease	DD70	Approved	[1]
Carprofen	DMHMP05	Pain	MG30-MG3Z	Approved	[2]
Celecoxib	DM6LOQU	Dysmenorrhea	GA34.3	Approved	[3]
Diflunisal	DM7EN8I	Osteoarthritis	FA00-FA05	Approved	[4]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[5]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[6]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[7]
FENBUFEN	DMXGDFK	Arthritis	FA20	Approved	[8]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[9]
Flurbiprofen	DMGN4BY	Osteoarthritis	FA00-FA05	Approved	[10]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[11]
Indomethacin	DMSC4A7	Bursitis		Approved	[1]
Ketoprofen	DMRKXPT	Bursitis		Approved	[12]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[13]
Meclofenamate Sodium	DMNL98G	Arthritis	FA20	Approved	[14]
Mefenamic acid	DMK7HFI	Dysmenorrhea	GA34.3	Approved	[15]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[16]
Nabumetone	DMAT2XH	Osteoarthritis	FA00-FA05	Approved	[17]
Naproxen	DMZ5RGV	Bursitis		Approved	[18]
Niflumic Acid	DMJ3I1Q	Rheumatoid arthritis	FA20	Approved	[19]
Phenylbutazone	DMAYL0T	Chronic pain	MG30	Approved	[20]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[21]
Tenoxicam	DMVAZP9	Rheumatoid arthritis	FA20	Approved	[22]
Tiaprofenic acid	DM23D7J	Osteoarthritis	FA00-FA05	Approved	[23]
Tolmetin	DMWUIJE	Osteoarthritis	FA00-FA05	Approved	[11]
Valdecoxib	DMAY7H4	Osteoarthritis	FA00-FA05	Approved	[24]
IMRECOXIB	DMVXLOD	N. A.	N. A.	Phase 4	[25]

10 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(S)-FLURBIPROFEN	DMF2O4T	Myalgia	FB56.2	Preregistration	[26]
CG-100649	DMIKMA9	Arthritis	FA20	Phase 3	[27]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[28]
ThermoProfen	DMPGH7N	Pain	MG30-MG3Z	Phase 3	[29]
Darbufelone	DMYVKM5	Asthma	CA23	Phase 2/3	[30]
CIMICOXIB	DMTKSVA	Pain	MG30-MG3Z	Phase 2	[31]
FK-3311	DML5AE4	Rheumatoid arthritis	FA20	Phase 2	[32]
SC-75416	DM58HR7	Pain	MG30-MG3Z	Phase 2	[33]
CA102N	DMYDNQ2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[34]
RWJ-67657	DM6YAGE	Arthritis	FA20	Phase 1	[35]

2 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Carbamate derivative 2	DMEWPQ6	N. A.	N. A.	Patented	[36]
PMID29130358-Compound-LonimacranthoideVI	DMTJEU5	N. A.	N. A.	Patented	[37]

32 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
INDOPROFEN	DM5QSKN	Gout	FA25	Withdrawn from market	[26]
GW-406381	DMJ4KQS	Neuropathic pain	8E43.0	Discontinued in Phase 3	[38]
PMI-001	DMDZBIQ	Lupus	4A40	Discontinued in Phase 3	[39]
PRINOMIDE TROMETHAMINE	DMI02PF	Inflammation	1A00-CA43.1	Discontinued in Phase 3	[40]
Apricoxib	DMR3Q82	Non-small-cell lung cancer	2C25.Y	Discontinued in Phase 2	[41]
CRx-401	DM39N7W	Type-2 diabetes	5A11	Discontinued in Phase 2	[42]
GSK-644784	DMUC9OS	Neuropathic pain	8E43.0	Discontinued in Phase 2	[38]
R-ketoprofen	DMHSUQ1	N. A.	N. A.	Discontinued in Phase 2	[26]
RQ-00317076	DM4GVZ9	Pain	MG30-MG3Z	Discontinued in Phase 2	[43]
S-2474	DMMSZ1A	Rheumatoid arthritis	FA20	Discontinued in Phase 2	[44]
TEBUFELONE	DMMUE8P	Pain	MG30-MG3Z	Discontinued in Phase 2	[45]
Tilmacoxib	DMPWSRA	Colon polyp	DB35	Discontinued in Phase 2	[46]
DUP 697	DMUMAHC	Pain	MG30-MG3Z	Discontinued in Phase 1	[47]
E-6087	DM79MI4	Pain	MG30-MG3Z	Discontinued in Phase 1	[48]
GR-253035	DMWY2F6	Alzheimer disease	8A20	Discontinued in Phase 1	[49]
SC-57666	DMIVRWS	Rheumatoid arthritis	FA20	Discontinued in Phase 1	[45]
ATLIPROFEN METHYL ESTER	DMS2FB3	Inflammation	1A00-CA43.1	Terminated	[1]
Flosulide	DM6OIJ1	Pain	MG30-MG3Z	Terminated	[50]
FR-123826	DM0582D	Rheumatoid arthritis	FA20	Terminated	[51]
L-745337	DMOQIWH	Asthma	CA23	Terminated	[52]
L-768277	DM7J6QH	Hyperthermia	MG26	Terminated	[53]
Nimesulide	DMR1NMD	Metastatic colorectal cancer	2B91	Terminated	[54]
NMI-150	DMX6DNZ	Pain	MG30-MG3Z	Terminated	[55]
NS398	DMINUWH	Endometriosis	GA10	Terminated	[56]
ON-09300	DMMLXRG	Solid tumour/cancer	2A00-2F9Z	Terminated	[1]
RPR 200765A	DM1U0TB	Rheumatoid arthritis	FA20	Terminated	[57]
RWJ-63556	DMUDE1T	Arthritis	FA20	Terminated	[58]
S-33516	DMF710M	Arthritis	FA20	Terminated	[59]
SB 203580	DMAET6F	N. A.	N. A.	Terminated	[60]
SC-236	DMO1URE	Solid tumour/cancer	2A00-2F9Z	Terminated	[61]
SC-58125	DM874YU	N. A.	N. A.	Terminated	[62]
SC-58451	DMVGK24	N. A.	N. A.	Terminated	[63]

126 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(11H-Dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid	DMSUPVE	Discovery agent	N.A.	Investigative	[64]
(11H-Dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid	DM5ZTXL	Discovery agent	N.A.	Investigative	[64]
(11H-Dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid	DMBY623	Discovery agent	N.A.	Investigative	[64]
(E)-2-(4-(methylsulfonyl)styryl)furan	DMH2U4Z	Discovery agent	N.A.	Investigative	[65]
(E)-2-(4-(methylsulfonyl)styryl)thiophene	DMDFE1R	Discovery agent	N.A.	Investigative	[65]
(E)-3-(4-(methylsulfonyl)styryl)thiophene	DMUS0D8	Discovery agent	N.A.	Investigative	[65]
(E)-4-(2-(furan-2-yl)vinyl)benzenesulfonamide	DMDF7M4	Discovery agent	N.A.	Investigative	[65]
(E)-4-(2-(thiophen-2-yl)vinyl)benzenesulfonamide	DM7204O	Discovery agent	N.A.	Investigative	[65]
(E)-4-(2-(thiophen-3-yl)vinyl)benzenesulfonamide	DMTAB8W	Discovery agent	N.A.	Investigative	[65]
(R)-2-(4-Isobutyl-phenyl)-N-phenyl-propionamide	DMAD4JY	Discovery agent	N.A.	Investigative	[26]
(Z)-2'-des-methyl sulindac sulfide	DM0OEQJ	Discovery agent	N.A.	Investigative	[66]
1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene	DMST60D	Discovery agent	N.A.	Investigative	[67]
1,3-bis(nitrooxy)propan-2-yl 2-acetoxybenzoate	DMIK7XV	Discovery agent	N.A.	Investigative	[68]
1-(2-hydroxyphenyl)-3-p-tolylprop-2-en-1-one	DMAFS7J	Discovery agent	N.A.	Investigative	[69]
1-(4-(methylsulfonyl)phenyl)-1H-indole	DMCE7G0	Discovery agent	N.A.	Investigative	[70]
1-(4-(methylsulfonyl)phenyl)-1H-pyrrole	DMYFBRQ	Discovery agent	N.A.	Investigative	[70]
1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea	DMMSQLC	Discovery agent	N.A.	Investigative	[71]
1-(4-(methylsulfonyl)phenyl)-3-phenylurea	DMH7RY0	Discovery agent	N.A.	Investigative	[71]
1-(4-aminosulfonylphenyl)-2-(2-pyridyl)acetylene	DMWA6G1	Discovery agent	N.A.	Investigative	[72]
2'-hydroxy-3,4,5-trimethoxychalcone	DM5ACNU	Discovery agent	N.A.	Investigative	[69]
2'-Hydroxychalcone	DM8RTBS	Discovery agent	N.A.	Investigative	[69]
2,3-dimethoxy-2'-hydroxychalcone	DML92OK	Discovery agent	N.A.	Investigative	[69]
2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl	DMWNJ84	Discovery agent	N.A.	Investigative	[73]
2,4'-Dimethoxy-5,3'-dipropyl-biphenyl	DM94NM7	Discovery agent	N.A.	Investigative	[73]
2,4-dimethoxy-2'-hydroxychalcone	DMP9BZU	Discovery agent	N.A.	Investigative	[69]
2,6-dihydroxy-1,7-dimethoxyxanthone	DM5QEUC	Discovery agent	N.A.	Investigative	[74]
2-(2,3,4-trimethoxyphenyl)-1H-indene	DMFU1PK	Discovery agent	N.A.	Investigative	[67]
2-(2-(2,6-dimethylphenylamino)phenyl)acetic acid	DMJ2DE4	Discovery agent	N.A.	Investigative	[75]
2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one	DMIQBXD	Discovery agent	N.A.	Investigative	[76]
2-(4-(methylsulfonyl)phenyl)-3-phenylquinoline	DMVD6HE	Discovery agent	N.A.	Investigative	[77]
2-(4-(methylsulfonyl)phenyl)pyridine	DM1TZNK	Discovery agent	N.A.	Investigative	[70]
2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid	DMRNOM6	Discovery agent	N.A.	Investigative	[78]
2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid	DMCL9E6	Discovery agent	N.A.	Investigative	[78]
2-(p-Methylsulfonylbenzoyl)furan	DMLT635	Discovery agent	N.A.	Investigative	[70]
2-Benzyl-1,2-dihydro-indazol-3-one	DM1CB5J	Discovery agent	N.A.	Investigative	[76]
2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one	DMQIRY7	Discovery agent	N.A.	Investigative	[76]
2-Methyl-1,2-dihydro-indazol-3-one	DMDJHFQ	Discovery agent	N.A.	Investigative	[76]
2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one	DM1EJ6W	Discovery agent	N.A.	Investigative	[76]
2-Phenethyl-1,2-dihydro-indazol-3-one	DM0WMBC	Discovery agent	N.A.	Investigative	[76]
2-Phenyl-1,2-dihydro-indazol-3-one	DM28CLZ	Discovery agent	N.A.	Investigative	[76]
3 beta-O-acetyloleanolic acid	DM1L5IJ	Discovery agent	N.A.	Investigative	[79]
3,4-dibenzyloxy-2'-hydroxychalcone	DMBUT8A	Discovery agent	N.A.	Investigative	[69]
3,4-dihydroxyxanthone	DMTQX92	Discovery agent	N.A.	Investigative	[74]
3-(4-Methanesulfonyl-phenyl)-1-phenyl-propynone	DMSR2O3	Discovery agent	N.A.	Investigative	[80]
3-benzyloxy-4-methoxy-2'-hydroxychalcone	DMKD874	Discovery agent	N.A.	Investigative	[69]
3-Bromo-2'-hydroxy-4-methoxychalcone	DM1BALV	Discovery agent	N.A.	Investigative	[69]
4,5-Bis(4-chlorophenyl)-1,2-selenazole	DMIO254	Discovery agent	N.A.	Investigative	[81]
4,5-Bis(4-chlorophenyl)isothiazole	DMENLFY	Discovery agent	N.A.	Investigative	[82]
4,5-Bis(4-methoxyphenyl)-1,2-selenazole	DMKHD1M	Discovery agent	N.A.	Investigative	[81]
4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one	DMI39QT	Discovery agent	N.A.	Investigative	[82]
4,5-Bis(4-methoxyphenyl)isothiazole	DM90DV6	Discovery agent	N.A.	Investigative	[82]
4-((4-methoxyphenyl)diazenyl)benzenesulfonamide	DMNAT1D	Discovery agent	N.A.	Investigative	[83]
4-(3-hydroxy-benzylideneamino)-benzenesulfonamide	DMY2OVL	Discovery agent	N.A.	Investigative	[84]
4-(3-methoxy-benzylideneamino)-benzenesulfonamide	DMO8SQA	Discovery agent	N.A.	Investigative	[84]
4-(3-nitro-benzylideneamino)-benzenesulfonamide	DMD94OB	Discovery agent	N.A.	Investigative	[84]
4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole	DMZBEYO	Discovery agent	N.A.	Investigative	[81]
4-(4-fluoro-benzylideneamino)-benzenesulfonamide	DMRJD75	Discovery agent	N.A.	Investigative	[84]
4-(4-fluoro-phenyliminomethyl)-benzenesulfonamide	DMK8DCF	Discovery agent	N.A.	Investigative	[84]
4-(4-hydroxy-benzylideneamino)-benzenesulfonamide	DMNY0I5	Discovery agent	N.A.	Investigative	[84]
4-(4-methoxy-benzylideneamino)-benzenesulfonamide	DM2OR8E	Discovery agent	N.A.	Investigative	[84]
4-(4-methyl-benzylideneamino)-benzenesulfonamide	DMZSQ04	Discovery agent	N.A.	Investigative	[84]
4-(4-methyl-phenyliminomethyl)-benzenesulfonamide	DMV0S4U	Discovery agent	N.A.	Investigative	[84]
4-(4-nitro-benzylideneamino)-benzenesulfonamide	DMM86YK	Discovery agent	N.A.	Investigative	[84]
4-(benzylideneamino)benzenesulfonamide	DM03BQD	Discovery agent	N.A.	Investigative	[84]
4-amino-N-(4-chlorophenyl)benzenesulfonamide	DMCUSD4	Discovery agent	N.A.	Investigative	[85]
4-amino-N-(4-iodophenyl)benzenesulfonamide	DMN19QP	Discovery agent	N.A.	Investigative	[85]
4-benzyloxy-2'-hydroxychalcone	DMDC7TL	Discovery agent	N.A.	Investigative	[69]
4-fluoro-N-(4-(methylsulfonyl)phenyl)aniline	DMV6M5U	Discovery agent	N.A.	Investigative	[70]
4-phenyliminomethyl-benzenesulfonamide	DM9J5TZ	Discovery agent	N.A.	Investigative	[84]
5,3'-Dipropyl-biphenyl-2,4'-diol	DMJRXLD	Discovery agent	N.A.	Investigative	[73]
5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline	DMCP5U8	Discovery agent	N.A.	Investigative	[86]
5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole	DMY0P86	Discovery agent	N.A.	Investigative	[81]
5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole	DMEV8WS	Discovery agent	N.A.	Investigative	[81]
5-Ethyl-3,4-diphenyl-isoxazole	DMRIGXA	Discovery agent	N.A.	Investigative	[87]
5-methoxy-2-(4-(methylsulfonyl)phenyl)-1H-indole	DMG2HSU	Discovery agent	N.A.	Investigative	[88]
5-Methyl-3,4-diphenyl-isoxazole	DM0G2N5	Discovery agent	N.A.	Investigative	[87]
5-Phenyl-pentanoic acid benzyl-hydroxy-amide	DM3B6A8	Discovery agent	N.A.	Investigative	[89]
5-thia-8,11,14,17-eicosatetraenoic acid	DMF4RGW	Discovery agent	N.A.	Investigative	[5]
6,7'-oxybis(2-phenyl-4H-chromen-4-one)	DMT09YC	Discovery agent	N.A.	Investigative	[90]
8alpha,19-dihydroxylabd-13 E-en-15-oic acid	DM7K2DN	Discovery agent	N.A.	Investigative	[91]
alpha-linolenic acid	DMY64HE	Discovery agent	N.A.	Investigative	[5]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[92]
Bimetopyrole	DMPR14J	Pain	MG30-MG3Z	Investigative	[47]
C-myb	DMA5Z2G	Pain	MG30-MG3Z	Investigative	[93]
CLEMATOMANDSHURICA SAPONIN A	DM4SKYA	Discovery agent	N.A.	Investigative	[94]
CLEMATOMANDSHURICA SAPONIN B	DMNWXOC	Discovery agent	N.A.	Investigative	[94]
CR-4174	DM3M5AW	Inflammation	1A00-CA43.1	Investigative	[95]
CX-9051	DM526C9	Solid tumour/cancer	2A00-2F9Z	Investigative	[95]
DFU	DMUM84K	Pain	MG30-MG3Z	Investigative	[96]
Firocoxib	DMP6GNY	Discovery agent	N.A.	Investigative	[97]
Fluoro loxoprofen	DMJS62X	Discovery agent	N.A.	Investigative	[98]
Furan-3-yl(4-(methylsulfonyl)phenyl)methanone	DMPC6YL	Discovery agent	N.A.	Investigative	[70]
GW-637185X	DMX59A0	Discovery agent	N.A.	Investigative	[99]
Heme	DMGC287	Discovery agent	N.A.	Investigative	[100]
HONOKIOL	DMJWT3X	Discovery agent	N.A.	Investigative	[73]
L-748780	DMJZXAF	Discovery agent	N.A.	Investigative	[101]
L-761000	DM0A2MG	Discovery agent	N.A.	Investigative	[101]
LM-4108	DMWLMTD	Discovery agent	N.A.	Investigative	[102]
METHYLHONOKIOL	DM9YE6K	Discovery agent	N.A.	Investigative	[73]
Microxine	DM7Y9AD	Pain	MG30-MG3Z	Investigative	[103]
N-(1H-indazol-5-yl)acetamide	DMIMJNU	Discovery agent	N.A.	Investigative	[104]
N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide	DMSJX1H	Discovery agent	N.A.	Investigative	[105]
N-(3-phenoxy-4-pyridinyl)ethanesulfonamide	DMXF46V	Discovery agent	N.A.	Investigative	[106]
N-(3-phenylamino-4-pyridinyl)methanesulfonamide	DMJB7SE	Discovery agent	N.A.	Investigative	[105]
Nectamazin C	DMO0Q1F	Discovery agent	N.A.	Investigative	[107]
NEOLIGNAN 9-NOR-7,8-DEHYDRO-ISOLICARIN B	DMKFPA9	Discovery agent	N.A.	Investigative	[107]
Nitroflurbiprofen	DMWCV48	Discovery agent	N.A.	Investigative	[108]
NSC-27236	DMANZIE	Discovery agent	N.A.	Investigative	[83]
OCOPHYLLALS A	DMT59UG	Discovery agent	N.A.	Investigative	[107]
Ocophyllals b	DMEUPVF	Discovery agent	N.A.	Investigative	[107]
Oxametacin	DMWVLG1	Discovery agent	N.A.	Investigative	[109]
Oxindole 94	DMPFD6Y	Pain	MG30-MG3Z	Investigative	[110]
PAC-10649	DMKL6IC	Arthritis	FA20	Investigative	[111]
PHENIDONE	DMJD8XN	Discovery agent	N.A.	Investigative	[76]
Prifelone	DMLI4RF	Discovery agent	N.A.	Investigative	[112]
Primary alcohol metabolite of celecoxib	DMA8GI6	Discovery agent	N.A.	Investigative	[113]
Prostaglandin G2	DME74SP	Discovery agent	N.A.	Investigative	[100]
Resveratrol Potassium3-Sulfate	DMN1RLA	Discovery agent	N.A.	Investigative	[114]
Resveratrol Potassium4,-Sulfate	DMMFP57	Discovery agent	N.A.	Investigative	[114]
SB 239063	DM201Q7	Pain	MG30-MG3Z	Investigative	[115]
SC-558	DMAZLKX	Discovery agent	N.A.	Investigative	[116]
Silicon-modified indomethacin	DM5ZILV	Arthritis	FA20	Investigative	[95]
TENOSAL	DMMLSZ4	Rheumatoid arthritis	FA20	Investigative	[117]
THIOCTIC ACID	DMNFCXW	Discovery agent	N.A.	Investigative	[81]
Wogonin	DMGCF51	Discovery agent	N.A.	Investigative	[69]
XGP-110	DM96FTS	Arthritis	FA20	Investigative	[95]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [2] Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators. J Med Chem. 2006 Dec 28;49(26):7588-91.
• [3] Pfizer. Product Development Pipeline. March 31 2009.
• [4] Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc. 2001 Apr;132(4):451-6.
• [5] Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
• [6] Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
• [7] The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study. J Orthop Surg Res. 2009 May 26;4:17.
• [8] Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804.
• [9] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [10] Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
• [11] Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
• [12] Probing the skin permeation of fish oil/EPA and ketoprofen-3. Effects on epidermal COX-2 and LOX. Prostaglandins Leukot Essent Fatty Acids. 2007 Jun;76(6):357-62.
• [13] Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J. 2009 Jul;34(1):200-8.
• [14] Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine. Am J Physiol Renal Physiol. 2001 Nov;281(5):F975-82.
• [15] Systematic pharmacological approach to the characterization of NSAIDs. Prostaglandins Leukot Essent Fatty Acids. 1998 Jul;59(1):55-62.
• [16] Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum. 1997 Jun;26(6 Suppl 1):21-7.
• [17] Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
• [18] Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
• [19] Rat ovulation, implantation and decidualization are severely compromised by COX-2 inhibitors. Front Biosci. 2007 May 1;12:3333-42.
• [20] COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005 Oct;52(4):302-6.
• [21] Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
• [22] The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis. Turk J Gastroenterol. 2005 Sep;16(3):138-42.
• [23] Effects of tiaprofenic acid on the concentration and metabolism of proteoglycans in normal and degenerating canine articular cartilage. J Clin Pharmacol. 1990 Sep;30(9):808-14.
• [24] Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78.
• [25] Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2270-2.
• [26] 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
• [27] Pharmacokinetic, pharmacodynamic, and safety/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase i, randomized, multiple-dose study in healthy Korean men and women. Clin Ther. 2015 Jan 1;37(1):197-210.
• [28] Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammator... Bioorg Med Chem Lett. 2005 Apr 1;15(7):1793-7.
• [29] Topical NSAID therapy for musculoskeletal pain. Pain Med. 2010 Apr;11(4):535-49.
• [30] Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013 May 1;21(9):2551-9.
• [31] Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs.Vet J.2014 Apr;200(1):77-81.
• [32] Effects of the COX-2 inhibitor FK3311 on ischemia - reperfusion injury in the rat lung. J Invest Surg. 2007 May-Jun;20(3):175-80.
• [33] Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and ... Clin Pharmacol Ther. 2008 Jun;83(6):857-66.
• [34] National Cancer Institute Drug Dictionary (drug name CA102N).
• [35] Monocyte intracellular cytokine production during human endotoxaemia with or without a second in vitro LPS challenge: effect of RWJ-67657, a p38 MAP-kinase inhibitor, on LPS-hyporesponsiveness. Clin Exp Immunol. 2002 Feb;127(2):337-43.
• [36] Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66.
• [37] Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
• [38] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [39] Development of a botanical anti-arthritis drug, PMI-001. SBIR.STTR America's Seed Fund.
• [40] Dexketoprofene, selective cox-1 inhibitor nsaids, without gastrointestinal injury in rats. Acta Gastroenterol Latinoam. 2002 May;32(1):17-20.
• [41] Apricoxib, a COX-2 inhibitor for the potential treatment of pain and cancer. IDrugs. 2009 Nov;12(11):711-22.
• [42] ClinicalTrials.gov (NCT00506298) Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes. U.S. National Institutes of Health.
• [43] Clinical pipeline report, company report or official report of raqualia.
• [44] Effects of S-2474, a novel nonsteroidal anti-inflammatory drug, on amyloid beta protein-induced neuronal cell death. Br J Pharmacol. 2001 Oct;134(3):673-81.
• [45] New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflamm... J Med Chem. 1998 Mar 26;41(7):1124-37.
• [46] 4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a ... J Med Chem. 2002 Mar 28;45(7):1511-7.
• [47] Current status of COX-2 inhibitors. Mini Rev Med Chem. 2008 Jan;8(1):73-90.
• [48] Enantioselective HPLC determination of E-6087, a new COX-2 inhibitor, in human plasma: Validation and pharmacokinetic application. Chirality. 2004 May 15;16(5):302-8.
• [49] Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. Gut. 2005 May; 54(5): 608-616.
• [50] Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive heymann nephritis in the rat. Kidney Int. 1999 Nov;56(5):1770-8.
• [51] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007983)
• [52] Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect ... J Pharmacol Exp Ther. 1995 Sep;274(3):1531-7.
• [53] Characterization of the in vitro oxidative metabolites of the COX-2 selective inhibitor L-766,112. Bioorganic & Medicinal Chemistry Letters Volume 7, Issue 1, 7 January 1997, Pages 53-56.
• [54] Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
• [55] Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships. Iran J Pharm Res. 2011 Autumn; 10(4): 655-683.
• [56] New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202.
• [57] The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy. Bioorg Med Chem. 2001 Feb;9(2):537-54.
• [58] Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J Pharmacol Exp Ther. 1997 Aug;282(2):1094-101.
• [59] S 33516 Servier preclinical data. R & D Focus Drug News. July 12, 1999.
• [60] Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology. 2000 May;47(2-3):185-201.
• [61] Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice. Mol Cancer Ther. 2004 Apr;3(4):417-24.
• [62] Identification and optimisation of a novel series of pyrimidine based cyclooxygenase-2 (COX-2) inhibitors. Utilisation of a biotransformation appro... Bioorg Med Chem Lett. 2009 Aug 1;19(15):4509-14.
• [63] Novel 1,2-diarylcyclobutenes: Selective and orally active cox-2 inhibitors, Bioorg. Med. Chem. Lett. 6(22):2677-2682 (1996).
• [64] Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids. J Med Chem. 1986 Aug;29(8):1436-41.
• [65] Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41.
• [66] The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3271-4.
• [67] 'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors. Bioorg Med Chem. 2007 Sep 15;15(18):6109-18.
• [68] Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: synthesis, biological evalu... Bioorg Med Chem Lett. 2009 Jun 1;19(11):3014-8.
• [69] Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3.
• [70] Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71.
• [71] Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1336-9.
• [72] Synthesis and cyclooxygenase inhibitory activities of linear 1-(methanesulfonylphenyl or benzenesulfonamido)-2-(pyridyl)acetylene regioisomers. Bioorg Med Chem. 2008 Feb 15;16(4):1948-56.
• [73] Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65.
• [74] Selective cyclooxygenase-2 inhibitors from Calophyllum membranaceum. J Nat Prod. 2005 Oct;68(10):1514-8.
• [75] Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib. J Biol Chem. 2007 Jun 1;282(22):16379-90.
• [76] Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
• [77] Design, synthesis and biological evaluation of new 2,3-diarylquinoline derivatives as selective cyclooxygenase-2 inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1029-33.
• [78] Synthesis and biological activity of new anti-inflammatory compounds containing the 1,4-benzodioxine and/or pyrrole system. Bioorg Med Chem. 2007 Jul 15;15(14):4876-90.
• [79] Nitrogen-containing phorbol esters from Croton ciliatoglandulifer and their effects on cyclooxygenases-1 and -2. J Nat Prod. 2006 Jun;69(6):887-90.
• [80] Synthesis and biological evaluation of 1,3-diphenylprop-2-yn-1-ones as dual inhibitors of cyclooxygenases and lipoxygenases. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4842-5.
• [81] Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9.
• [82] Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68.
• [83] Selective COX-2 inhibitors. Part 1: synthesis and biological evaluation of phenylazobenzenesulfonamides. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4440-3.
• [84] Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706.
• [85] Analgesic agents without gastric damage: design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors. Bioorg Med Chem. 2007 Jan 15;15(2):1014-21.
• [86] 1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthas... J Med Chem. 2000 May 4;43(9):1841-51.
• [87] Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. J Med Chem. 2004 Sep 23;47(20):4881-90.
• [88] Synthesis and biological evaluation of new 4-carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors. Bioorg Med Chem. 2009 Jul 15;17(14):5312-7.
• [89] Differential effects of a series of hydroxamic acid derivatives on 5-lipoxygenase and cyclooxygenase from neutrophils and 12-lipoxygenase from plat... J Med Chem. 1989 Aug;32(8):1836-42.
• [90] Synthesis of biflavones having a 6-O-7'' linkage and effects on cyclooxygenase-2 and inducible nitric oxide synthase. Bioorg Med Chem Lett. 2009 Jan 1;19(1):74-6.
• [91] Cyclooxygenase (COX)-1 and -2 inhibitory labdane diterpenes from Crassocephalum mannii. J Nat Prod. 2008 Jun;71(6):1070-3.
• [92] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [93] Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB. Cancer Res. 2000 Apr 1;60(7):1805-9.
• [94] Triterpene saponins from clematis mandshurica. J Nat Prod. 2006 Nov;69(11):1591-5.
• [95] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1376).
• [96] Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem Biophys Res Commun. 2000 Jul 5;273(2):772-5.
• [97] SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2207-12.
• [98] Properties and synthesis of 2-{2-fluoro (or bromo)-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid: nonsteroidal anti-inflammatory drugs with low... J Med Chem. 2010 Nov 11;53(21):7879-82.
• [99] Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhib... Bioorg Med Chem Lett. 2009 Aug 1;19(15):4504-8.
• [100] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [101] From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 6(6):725-730 (1996).
• [102] Discovery of 3-(4-bromophenyl)-6-nitrobenzo[1.3.2]dithiazolium ylide 1,1-dioxide as a novel dual cyclooxygenase/5-lipoxygenase inhibitor that also ... Bioorg Med Chem. 2010 Jan 15;18(2):597-604.
• [103] Inhibition of cell cycle oscillation of DNA replication by a selective inhibitor of the cdc2 kinase family, butyrolactone I, in Xenopus egg extracts. Biochem Biophys Res Commun. 1994 Jan 28;198(2):536-45.
• [104] New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5.
• [105] Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibi... J Med Chem. 2009 Oct 8;52(19):5864-71.
• [106] Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors. J Med Chem. 2004 Dec 30;47(27):6749-59.
• [107] COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6922-5.
• [108] The cyclooxygenase inhibitor flurbiprofen reduces radiation-induced angiogenic growth factor secretion of squamous cell carcinoma cell lines. Ann N Y Acad Sci. 2004 Dec;1030:37-42.
• [109] Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors. J Med Chem. 2007 Dec 13;50(25):6367-82.
• [110] A selective inhibitor of p38 MAP kinase, SB202190, induced apoptotic cell death of a lipopolysaccharide-treated macrophage-like cell line, J774.1. Biochim Biophys Acta. 2000 Oct 18;1502(2):207-23.
• [111] PAC 10649 Pacific licensing offer, Worldwide excluding South Korea. R & D Focus Drug News. September 22, 2003.
• [112] Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
• [113] Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-hydroxymethylphenyl)-1-(4-aminosulfonylphenyl)-3-trifluoromethyl-1H-pyrazole an... Bioorg Med Chem. 2008 Nov 15;16(22):9694-8.
• [114] Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem. 2010 Jul 8;53(13):5033-43.
• [115] SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization. Pharm Res. 2001 Sep;18(9):1336-44.
• [116] In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218.
• [117] US patent application no. 6,274,627, Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor.